These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2759355)

  • 1. Continuous cell lines as substrates for biologicals. Draft position paper. Pharmaceutical Manufacturer's Association.
    Dev Biol Stand; 1989; 70():285-7. PubMed ID: 2759355
    [No Abstract]   [Full Text] [Related]  

  • 2. Conditional licensing of veterinary biologicals in the United States: a major manufacturer's perspective.
    Carlson MM; Chiang YW; Chu HJ
    Dev Biol (Basel); 2004; 117():97-103. PubMed ID: 15597624
    [No Abstract]   [Full Text] [Related]  

  • 3. Status of WHO concerning continuous cell lines as substrates for the production of biologicals.
    Grachev V; Magrath D
    Dev Biol Stand; 1989; 70():215-9. PubMed ID: 2759349
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 6. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

  • 7. Opposes manufacturer's policy on sale of antiflea product.
    Feldmann BM
    J Am Vet Med Assoc; 1997 Dec; 211(12):1505. PubMed ID: 9412673
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of the pharmaceutical industry in drug development and approval.
    Beleau MH
    Vet Hum Toxicol; 1998; 40 Suppl 2():17-9. PubMed ID: 9823577
    [No Abstract]   [Full Text] [Related]  

  • 9. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
    Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
    Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety issues relating to the use of mammalian cells as hosts.
    Petricciani JC
    Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering the therapies of tomorrow.
    Coghlan A
    New Sci; 1993 Apr; 138(1870):26-31. PubMed ID: 11656235
    [No Abstract]   [Full Text] [Related]  

  • 12. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
    Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
    [No Abstract]   [Full Text] [Related]  

  • 13. Introduction to the issues: recently developed methods for characterizing cell lines.
    Kozak RW
    Dev Biol Stand; 1992; 76():21-4. PubMed ID: 1478337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA withholds approval of anti-infection drug; manufacturer's stock price plunges.
    Wagner M
    Mod Healthc; 1992 Apr; 22(16):6. PubMed ID: 10117563
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current experience with biological products produced in various continuous cell lines. Summary and conclusions.
    Papermaster BW
    Dev Biol Stand; 1989; 70():227-9. PubMed ID: 2759350
    [No Abstract]   [Full Text] [Related]  

  • 17. Perspectives on the FDA status of drug products manufactured by the recombinant DNA technique.
    Korwek EL; Trinker DS
    Food Drug Cosmet Law J; 1981 Oct; 36(10):517-35. PubMed ID: 11650658
    [No Abstract]   [Full Text] [Related]  

  • 18. On the accountability problem of the pharmaceutical industry.
    Roberts CD
    Pharmazie; 1973 Jan; 28(1):49-51. PubMed ID: 4714241
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologicals: new horizons in pharmaceutical development.
    Oldham RK
    J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
    [No Abstract]   [Full Text] [Related]  

  • 20. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.